Abstract
Purpose: To evaluate the efficacy and tolerability of adjunctive perampanel (PER) in Chinese patients with focal-onset seizures, with or without secondarily generalized tonic-clonic seizures.Methods: Fifty-six patients aged 14–72 years were recruited consecutively in this single-center prospective observational study. All patients received PER as add-on treatment on the basis of clinical judgment. Seizure frequency, adverse events (AEs), and retention rates were obtained at 3 and 6 months after PER introduction.Results: The overall response rates were 60 and 71.1% after 3 and 6 months, respectively, and the freedom of seizures at the same points were reached in 8 and 15.8%. The retention rates were 89.3% at the 3-month follow-up and 67.9% at the 6-month follow-up. The overall incidence of adverse events was 55.4%. The leading reported AEs were dizziness (39.3%) and somnolence (25%).Conclusions: Our study confirmed the efficacy and tolerability of adjunctive PER in Chinese patients in real-life conditions. Based on our treatment experience, a lower maintenance dose of PER would be needed in Chinese patients.
Highlights
Epilepsy is one of the most common chronic diseases of the central nervous system, affecting about 50 million people worldwide [1]
Anti-seizure medication (ASM) therapy is the main treatment for epilepsy, but about 30% of patients still do not successfully respond to conventional ASMs and develop into refractory epilepsy [3]
Perampanel is approved as adjunctive therapy for focal-onset seizures with or without generalization and primary generalized tonic-clonic seizures in patients’ aged 12 years and older in more than 50 countries, and has been approved as monotherapy and adjunctive therapy for focal-onset seizures with or without secondarily generalized seizures in patients over 4 years of age in the United States [6]
Summary
Epilepsy is one of the most common chronic diseases of the central nervous system, affecting about 50 million people worldwide [1]. Perampanel, one of the latest ASMs, is a highly selective and non-competitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [4], which is the Efficacy and Tolerability of Perampanel main subtype of ionotropic glutamate receptor that mediates rapid excitatory neurotransmission in the central nervous system (CNS) and plays an important role in epileptic activity [5]. Double-blind, placebo-controlled trials and real-life studies have confirmed the efficacy and safety of perampanel as adjunctive therapy for focal and generalized seizures [7,8,9,10]. In September 2019, perampanel was approved for use in China as adjunctive treatment for focal-onset seizures, with or without secondarily generalized tonic-clonic seizures (sGTCS) in patients aged ≧12 years. The recent approval of perampanel means that few reallife studies on the use of perampanel in Chinese patients have been reported
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
